This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
The discovery and development of powerful immunotherapies for all types of cancer requires information and dialogue. Cancer Research Institute print and online resources make it easy to stay up-to-date on cancer immunotherapy research and treatment. CRI also offers information specifically for patients and their families, as well as for current and prospective donors.
If you would like more information, call us at (800) 99-CANCER or send us a message via our Contact Us page.
A browser plugin may be required for the PDF file found this page.
CRI.ContactUs
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.